Brepocitinib Tosylate Patent Expiration

Brepocitinib Tosylate was first introduced by Priovant Therapeutics Inc in its drug Lisraya on Aug 27, 2026.


Brepocitinib Tosylate Patents

Given below is the list of patents protecting Brepocitinib Tosylate, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Lisraya US11197867 Aminopyrimidinyl Compounds Aug 19, 2035 Priovant Therap
Lisraya US9663526 Aminopyrimidinyl Compounds Aug 19, 2035 Priovant Therap



Brepocitinib Tosylate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Brepocitinib Tosylate Generic API Manufacturers

Given below is the list of companies who have filed for Brepocitinib Tosylate generic, along with the locations of their manufacturing plants worldwide.